Can open-source drug R&D repower pharmaceutical innovation?
Open-source R&D initiatives are multiplying across biomedical research. Some of them-such as public-private partnerships-have achieved notable success in bringing new drugs to market economically, whereas others reflect the pharmaceutical industry's efforts to retool its R&D model. Is open innovation the answer to the innovation crisis? This Commentary argues that although it may likely be part of the solution, significant cultural, scientific, and regulatory barriers can prevent it from delivering on its promise.
Munos
B
B
Corporate Strategy, Eli Lilly and Company, Indianapolis, Indiana, USA. bhmunos@stanfordalumni.org
D000818:Animals; D055808:Drug Discovery / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends*; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D035703:Therapies, Investigational / Q000191:economics / Q000379:methods* / Q000592:standards / Q000639:trends*